First experience of a hemophilia monitoring platform: florio HAEMO.

hemophilia patient preference pharmacokinetics telemedicine

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 12 11 2021
revised: 11 01 2022
accepted: 05 02 2022
entrez: 21 3 2022
pubmed: 22 3 2022
medline: 22 3 2022
Statut: epublish

Résumé

florio HAEMO is a new hemophilia treatment monitoring application consisting of a patient smartphone application (app) and a web-based dashboard for healthcare professionals, providing several novel features, including activity tracking, wearable connectivity, kids and caregiver mode, and real-time pharmacokinetic factor level estimation. To assess intuitiveness, ease-of-use, and patient preference of florio HAEMO in Central Europe using a cross-sectional survey. This survey was conducted in six Central European countries between 9 December 2020 and 24 May 2021. The online questionnaire included 17 questions about overall satisfaction, ease-of-use, intuitiveness, and patient preference. Adults or children with hemophilia on regular prophylaxis and using the florio HAEMO app for a minimum of 1 week were invited to complete the online questionnaire by their treating physician. Sixty-six participants took part in the survey. The median duration for all respondents using the florio HAEMO app was 3 to 4 weeks. Overall, 89.4% of users reported being very satisfied or rather satisfied after using florio HAEMO. Of the 23 respondents who had switched from another hemophilia app, 87.0% indicated that they strongly preferred or preferred using florio HAEMO. Most florio HAEMO users reported that the app was very easy or rather easy to use (97.0%) and intuitive (94.0%). florio HAEMO had a positive impact on daily living, with 78.8% of users reporting that the app was very important or rather important to them. This survey suggests that florio HAEMO is an easy-to-use and intuitive app to assist self-management of home prophylaxis.

Sections du résumé

Background UNASSIGNED
florio HAEMO is a new hemophilia treatment monitoring application consisting of a patient smartphone application (app) and a web-based dashboard for healthcare professionals, providing several novel features, including activity tracking, wearable connectivity, kids and caregiver mode, and real-time pharmacokinetic factor level estimation.
Objectives UNASSIGNED
To assess intuitiveness, ease-of-use, and patient preference of florio HAEMO in Central Europe using a cross-sectional survey.
Methods UNASSIGNED
This survey was conducted in six Central European countries between 9 December 2020 and 24 May 2021. The online questionnaire included 17 questions about overall satisfaction, ease-of-use, intuitiveness, and patient preference. Adults or children with hemophilia on regular prophylaxis and using the florio HAEMO app for a minimum of 1 week were invited to complete the online questionnaire by their treating physician.
Results UNASSIGNED
Sixty-six participants took part in the survey. The median duration for all respondents using the florio HAEMO app was 3 to 4 weeks. Overall, 89.4% of users reported being very satisfied or rather satisfied after using florio HAEMO. Of the 23 respondents who had switched from another hemophilia app, 87.0% indicated that they strongly preferred or preferred using florio HAEMO. Most florio HAEMO users reported that the app was very easy or rather easy to use (97.0%) and intuitive (94.0%). florio HAEMO had a positive impact on daily living, with 78.8% of users reporting that the app was very important or rather important to them.
Conclusions UNASSIGNED
This survey suggests that florio HAEMO is an easy-to-use and intuitive app to assist self-management of home prophylaxis.

Identifiants

pubmed: 35308098
doi: 10.1002/rth2.12685
pii: S2475-0379(22)01173-6
pmc: PMC8918679
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12685

Informations de copyright

© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).

Références

Haemophilia. 2006 Mar;12(2):163-8
pubmed: 16476091
Haemophilia. 2020 Nov;26(6):999-1008
pubmed: 33084135
J Thromb Haemost. 2017 Dec;15(12):2461-2465
pubmed: 29119666
Haemophilia. 2021 May;27(3):417-424
pubmed: 33751755
J Health Econ. 2008 Sep;27(5):1275-84
pubmed: 18667254
Haemophilia. 2004 Nov;10(6):698-704
pubmed: 15569164
Hamostaseologie. 2019 Nov;39(4):339-346
pubmed: 30620988
Res Pract Thromb Haemost. 2018 May 20;2(3):535-548
pubmed: 30046759
Haemophilia. 2009 Mar;15(2):464-72
pubmed: 19226411
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):595-604
pubmed: 29222309
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):894-903
pubmed: 31668021
Haemophilia. 2017 Sep;23(5):728-735
pubmed: 28806858
Ther Adv Hematol. 2020 Oct 20;11:2040620720966888
pubmed: 33194165
BMJ Open. 2015 Feb 06;5(2):e006448
pubmed: 25659890

Auteurs

Ester Zapotocka (E)

Department of Pediatric Hematology/Oncology University Hospital Motol 2nd Faculty of Medicine Charles University Prague Czech Republic.

Angelika Batorova (A)

National Hemophilia Center Department of Hematology and Transfusion Medicine Faculty of Medicine of Comenius University and University Hospital Bratislava Slovakia.

Ernest Bilic (E)

Department of Pediatrics Division of Hematology and Oncology University Hospital Center Zagreb Zagreb Croatia.

Ana Boban (A)

Division of Hematology Department of Internal Medicine University Hospital Center Zagreb School of Medicine University of Zagreb Zagreb Croatia.

Carmen Escuriola Ettingshausen (C)

HZRM Hamophilie Zentrum Rhein Main Mörfelden-Walldorf Germany.

Barbara Faganel Kotnik (B)

Department of Hematology and Oncology University Children's Hospital University Medical Center Ljubljana Ljubljana Slovenia.

Radomira Hrdlickova (R)

Blood Center University Hospital Ostrava Ostrava Czech Republic.

Pawel Laguna (P)

Department of Pediatrics, Hematology, and Oncology Warsaw Medical University Warsaw Poland.

Jan Machal (J)

Department of Pediatric Hematology and Biochemistry Masaryk University and University Hospital Brno Brno Czech Republic.

Laszlo Nemes (L)

Medical Center of Hungarian Defense Forces Budapest Hungary.

Irena Preloznik Zupan (IP)

Department of Hematology University Medical Center Ljubljana Faculty of Medicine University of Ljubljana Ljubljana Slovenia.

Gediminas Puras (G)

Swedish Orphan Biovitrum AG Basel Switzerland.

Marianna Zombori (M)

Hemato-oncology Unit Heim Pal Children's Hospital Budapest Hungary.

Classifications MeSH